Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
gptkb:oxandrolone
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A14AA08
|
| gptkbp:CASNumber |
53-39-4
|
| gptkbp:chemicalFormula |
C19H30O3
|
| gptkbp:contraindication |
prostate cancer
pregnancy breast cancer in men |
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_III_(US)
|
| gptkbp:drugClass |
anabolic steroid
|
| https://www.w3.org/2000/01/rdf-schema#label |
Oxandrin
|
| gptkbp:legalStatus |
prescription only (US)
|
| gptkbp:marketedAs |
Savient Pharmaceuticals
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
liver toxicity
virilization cholesterol changes |
| gptkbp:synonym |
gptkb:oxandrolone
|
| gptkbp:usedFor |
weight gain
muscle wasting recovery from severe burns |
| gptkbp:bfsParent |
gptkb:oxandrolone
|
| gptkbp:bfsLayer |
8
|